These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 19838030

  • 1. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
    Kato T, Matsunaga Y, Motokawa S, Nakagaki S, Nagata N, Yoshida T, Muramatsu T, Kimura H, Ohashi Y, Kudou Y, Shino M, Yamazaki K, Boku N.
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [Abstract] [Full Text] [Related]

  • 3. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
    Kuboki Y, Ichimura T, Ogura M, Matsuda M, Suenaga M, Shinozaki E, Matsuzaka S, Chin K, Mizunuma N, Hatake K.
    Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
    Ishiguro T, Ishibashi K, Okada N, Kuwabara K, Miyazaki T, Yokoyama M, Matsuki M, Sano M, Inoue N, Ishida H.
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
    [Abstract] [Full Text] [Related]

  • 5. [Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].
    Imada H, Kawakami K, Hiraoka T, Higuchi S, Takahashi G, Aoyama T, Shinozaki E, Suenaga M, Matsuzaka S, Hama T.
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1425-30. PubMed ID: 17876140
    [Abstract] [Full Text] [Related]

  • 6. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
    Ueda H, Demizu M, Oosawa M, Chihara S, Nakanishi Y, Maeda C, Yano K, Kimura F, Iwakawa S.
    Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
    [Abstract] [Full Text] [Related]

  • 7. [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
    Kamisugi K, Matsusaka S, Imada H, Shoji D, Nakamoto E, Yokokawa T, Kawakami K, Hirata Y, Nawano K, Ogawa M, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T.
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1331-5. PubMed ID: 18701844
    [Abstract] [Full Text] [Related]

  • 8. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
    Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E.
    Acta Oncol; 2007 Aug; 46(8):1131-7. PubMed ID: 17851880
    [Abstract] [Full Text] [Related]

  • 9. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
    Shibata M, Shimura T, Nishina Y, Gonda K, Matsuo S, Abe H, Yajima Y, Nakamura I, Ohki S, Takenoshita S.
    Gan To Kagaku Ryoho; 2011 May; 38(5):797-801. PubMed ID: 21566440
    [Abstract] [Full Text] [Related]

  • 10. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
    Kimura T, Iwase K, Aono T, Nakai S, Fujii M, Nishikawa K, Matsuda C, Shimada K, Hirota M, Nasu S, Wada D, Hasegawa J, Tanaka Y.
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
    [Abstract] [Full Text] [Related]

  • 11. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
    Jung KH, Kil SY, Choi IK, Seo JH, Shin C, Kim YS, Kim JH.
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
    [No Abstract] [Full Text] [Related]

  • 12. [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
    Nishi T, Hamamoto Y, Uemoto J, Onodera K, Warita E, Yamanaka Y.
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2557-60. PubMed ID: 23235179
    [Abstract] [Full Text] [Related]

  • 13. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
    Tatsushima Y, Egashira N, Narishige Y, Fukui S, Kawashiri T, Yamauchi Y, Oishi R.
    Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
    Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, Sato A, Moriya Y, Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group.
    Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
    [Abstract] [Full Text] [Related]

  • 15. Oxaliplatin-induced immune mediated thrombocytopenia.
    Beg MS, Komrokji RS, Ahmed K, Safa MM.
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
    [Abstract] [Full Text] [Related]

  • 16. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
    Satoh T, Yamaguchi K, Boku N, Okamoto W, Shimamura T, Yamazaki K, Shi X, Mishima H.
    Invest New Drugs; 2012 Aug; 30(4):1511-8. PubMed ID: 21611734
    [Abstract] [Full Text] [Related]

  • 17. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
    Yoshimura T, Hirade K, Iihara H, Ishihara M, Komori Y, Okayasu S, Matsuura K, Yasuda T, Itoh Y.
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
    [Abstract] [Full Text] [Related]

  • 18. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.
    Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, Tanemura H, Oba K, Nakao A, Sakamoto J, Mishima H.
    Hepatogastroenterology; 2009 Oct; 56(94-95):1346-53. PubMed ID: 19950789
    [Abstract] [Full Text] [Related]

  • 19. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [Abstract] [Full Text] [Related]

  • 20. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, Polyzos K, Tsigris C, Mantas D, Papachristodoulou A, Nikiteas N, Karavokyros JG, Felekouras E, Griniatsos J, Giannopoulos A, Kouraklis G.
    Oncology; 2009 Jun; 76(1):36-41. PubMed ID: 19033714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.